Ciprofloxacin nano-niosomes for targeting intracellular infections: An in vitro evaluation

Journal of Nanoparticle Research

Volumn 15, Issue 4, 2013, Pages

  Akbari, Vajihe ^a   Abedi, Daryoush ^a   Pardakhty, Abbas ^b   Sadeghi Aliabadi, Hojjat ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Ciprofloxacin; Intracellular infection; Macrophages; Niosomes

Indexed keywords

ANTIBIOTICS; BACTERIA; MACROPHAGES; MICROWAVE INTEGRATED CIRCUITS;

ANTI-BACTERIAL ACTIVITY; ANTI-MICROBIAL ACTIVITY; BIOLOGICAL PROPERTIES; CIPROFLOXACIN; INTRACELLULAR DISTRIBUTION; INTRACELLULAR INFECTION; MINIMUM INHIBITORY CONCENTRATION; NIOSOMES;

DRUG DELIVERY;

CIPROFLOXACIN; NIOSOME;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; ESCHERICHIA COLI; IN VITRO STUDY; INFECTION; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHAGOCYTE; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; TARGET CELL DESTRUCTION; ZETA POTENTIAL;

EID: 84874717768     PISSN: 13880764     EISSN: 1572896X     Source Type: Journal    
DOI: 10.1007/s11051-013-1556-y     Document Type: Article

References (35)

1. Abdelbary G, El-gendy N (2008) Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech 9(3):740-747
2. Baillie A, Florence A, Hume L, Muirhead G, Rogerson A (1985) The preparation and properties of niosomes - non-ionic surfactant vesicles. J Pharm Pharmacol 37(12):863-868
3. Bhaskaran S, Panigrahi L (2002) Formulation and evaluation of niosomes using different non-ionic surfactants. Indian J Pharm Sci 64(1):63-65
4. Caracciolo G, Pozzi D, Caminiti R, Marianecci C, Moglioni S, Carafa M, Amenitsch H (2008) Effect of hydration on the structure of solid-supported niosomal membranes investigated by in situ energy dispersive X-ray diffraction. Chem Phys Lett 462(4):307-312
5. Champion JA, Walker A, Mitragotri S (2008) Role of particle size in phagocytosis of polymeric microspheres. Pharm Res 25(8):1815-1821
6. Chono S, Tauchi Y, Morimoto K (2006) Influence of particle size on the distributions of liposomes to atherosclerotic lesions in mice. Drug Dev Ind Pharm 32(1):125-135 (Pubitemid 43220921)
7. Chono S, Tanino T, Seki T, Morimoto K (2007) Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification. J Pharm Pharmacol 59(1):75-80 (Pubitemid 46133045)
8. Ellbogen MH, Olsen KM, Gentry-Nielsen MJ, Preheim LC (2003) Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of Pneumococcal pneumonia. J Antimicrob Chemother 51(1):83-91 (Pubitemid 36163831)
9. Epstein-Barash H, Gutman D, Markovsky E, Mishan-Eisenberg G, Koroukhov N, Szebeni J, Golomb G (2010) Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death. J Controlled Release 146(2):182-195
10. Goyal P, Goyal K, Kumar SGV, Singh A, Katare OP, Mishra DN (2005) Liposomal drug delivery systems - clinical applications. Acta Pharm 55(1):1-25 (Pubitemid 40562616)
11. Gubernator J, Drulis-Kawa Z, Dorotkiewicz-Jach A, Doroszkiewicz W, Kozubek A (2007) In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against Gram-negative clinical bacterial strains. Lett Drug Des Discov 4(4):297-304 (Pubitemid 46708895)
12. Hamrick TS, Diaz AH, Havell EA, Horton JR, Orndorff PE (2003) Influence of extracellular bactericidal agents on bacteria within macrophages. Infect Immun 71(2):1016-1019 (Pubitemid 36150801)
13. Hernández-Borrell J, Montero MT (2003) Does ciprofloxacin interact with neutral bilayers? An aspect related to its antimicrobial activity. Int J Pharm 252(1-2):149-157 (Pubitemid 36126623)
14. Hofmann T (2012) New developments in inhaled antibiotics for the treatment of Pseudomonas aeruginosa. Curr Pharm Des 18(5):683-695
15. Holmes B, Quie PG, Windhorst DB, Pollara B, Good RA (1966) Protection of phagocytized bacteria from the killing action of antibiotics. Nature 210(5041):1131
16. Junyaprasert VB, Teeranachaideekul V, Supaperm T (2008) Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. AAPS PharmSciTech 9(3):851-859
17. Kaufmann SHE (2011) Intracellular pathogens: living in an extreme environment. Immunol Rev 240(1):5-10
18. Lawrence JW, Claire DC, Weissig V, Rowe TC (1996) Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. Mol Pharmacol 50(5):1178
19. Lee SC, Lee KE, Kim JJ, Lim SH (2005) The effect of cholesterol in the liposome bilayer on the stabilization of incorporated retinol. J Liposome Res 15(3-4):157-166 (Pubitemid 43062264)
20. Maurin M, Raoult D (1996) Optimum treatment of intracellular infection. Drugs 52(1):45
21. Moazeni E, Gilani K, Sotoudegan F, Pardakhty A, Najafabadi AR, Ghalandari R, Fazeli MR, Jamalifar H (2010) Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery. J Microencapsul 27(7):618-627
22. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2):55-63 (Pubitemid 14203433)
23. Mullaicharam A, Murthy R (2004) Lung accumulation of niosome-entrapped rifampicin following intravenous and intratracheal administration in the rat. STP Pharm Sci 14(2):99-104 (Pubitemid 38506436)
24. Mullaicharam A, Murthy R (2006) Lung accumulation of niosome-entrapped gentamicin sulfate follows intravenous and intratracheal administration in rats. J Drug Deliv Sci Technol 16(2):109-113
25. Naresh RAR, Udupa N, Devi P (1996) Niosomal plumbagin with reduced toxicity and improved anticancer activity in BALB/C mice. J Pharm Pharmacol 48(11):1128-1132 (Pubitemid 126449481)
26. Oh YK, Nix DE, Straubinger RM (1995) Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob Agents Chemother 39(9):2104-2111
27. Pandey VP, Deivasigamani K (2009) Preparation and characterization of ofloxacin non-ionic surfactant vesicles for ophthalmic use. J Pharm Res 2(7):1330-1334
28. Pardakhty A, Foroumadi A, Hashemi M, Rajabalian S, Heidari MR (2007) In vitro cytotoxicity and phototoxicity of N-piperazinyl quinoline derivatives with a 2-thienyl group. Toxicol In Vitro 21(6):1031-1038 (Pubitemid 47238230)
29. Rani NP, Suriyaprakash TNK, Senthamarai R (2010) Formulation and evaluation of rifampicin and gatifloxacin niosomes on logarithmic-phase cultures of Mycobacterium tuberculosis. Int J Pharm Biol Sci 1:379-387
30. Rous P, Jones F (1916) The protection of pathogenic microorganisms by living tissue cells. J Exp Med 23(5):601
31. Sadeghi-Aliabadi H, Sajjadi SE, Khodamoradi M (2009) Cytotoxicity of Euphorbia macroclada on MDA-MB-468 breast cancer cell line. Iran J Pharm Sci 5(2):103-108
32. Shahiwala A, Misra A (2002) Studies in topical application of niosomally entrapped Nimesulide. J Pharm Pharm Sci 5(3):220
33. Varshosaz J, Pardakhty A, Hajhashemi V, Najafabadi AR (2003) Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Delivery 10(4):251-262 (Pubitemid 37494139)
34. Wong JP, Yang H, Blasetti KL, Schnell G, Conley J, Schofield LN (2003) Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J Controlled Release 92(3):265-273 (Pubitemid 38366150)
35. Zaru M, Sinico C, De Logu A, Caddeo C, Lai F, Manca ML, Fadda AM (2009) Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: in vitro and in vivo evaluation. J Liposome Res 19(1):68-76